Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma

Cancer

Volumn 120, Issue 12, 2014, Pages 1794-1799

  Porten, Sima ^a   Siefker Radtke, Arlene O ^a   Xiao, Lianchun ^a   Margulis, Vitaly ^a,b   Kamat, Ashish M ^a   Wood, Christopher G ^a   Jonasch, Eric ^a   Dinney, Colin P N ^a   Matin, Surena F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

chemotherapy; renal pelvis cancer; surgical treatment; survival; ureteral cancer; urothelial carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; NEPHROURETERECTOMY; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

CHEMOTHERAPY; RENAL PELVIS CANCER; SURGICAL TREATMENT; SURVIVAL; URETERAL CANCER; UROTHELIAL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84902135029     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28655     Document Type: Article

References (30)

1. Brown GA, Busby JE, Wood CG, et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 2006; 98: 1176-1180.
2. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG,. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998; 52: 594-601.
3. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009; 115: 1224-1233.
4. Raman JD, Messer J, Sielatycki JA, Hollenbeak CS,. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int. 2011; 107: 1059-1064.
5. Lughezzani G, Jeldres C, Isbarn H, et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer. 2009; 45: 3291-3297.
6. Munoz JJ, Ellison LM,. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000; 164: 1523-1525.
7. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Eur Urol. 2005; 48: 202-205; discussion 205-206.
8. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001; 19: 4005-4013.
9. Kaag MG, O'Malley RL, O'Malley P, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010; 58: 581-587.
10. Lane BR, Smith AK, Larson BT, et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer. 2010; 116: 2967-2973.
11. Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010; 116: 3127-3134.
12. Igawa M, Urakami S, Shiina H, et al. Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol Int. 1995; 55: 74-77.
13. Brown GA, Matin SF, Busby JE, et al. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology. 2007; 70: 252-256.
14. Keeley FX, Kulp DA, Bibbo M, McCue PA, Bagley DH,. Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. J Urol. 1997; 157: 33-37.
15. Williams SK, Denton KJ, Minervini A, et al. Correlation of upper-tract cytology, retrograde pyelography, ureteroscopic appearance, and ureteroscopic biopsy with histologic examination of upper-tract transitional cell carcinoma. J Endourol. 2008; 22: 71-76.
16. Fritsche HM, Novara G, Burger M, et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol. 2012; 30: 666-672.
17. Remzi M, Haitel A, Margulis V, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 2009; 103: 307-311.
18. Cho KS, Hong SJ, Cho NH, Choi YD,. Grade of hydronephrosis and tumor diameter as preoperative prognostic factors in ureteral transitional cell carcinoma. Urology. 2007; 70: 662-666.
19. Simone G, Papalia R, Loreto A, Leonardo C, Sentinelli S, Gallucci M,. Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma. BJU Int. 2009; 103: 1052-1057.
20. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004.
21. Roscigno M, Shariat SF, Margulis V, et al. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol. 2009; 56: 512-518.
22. Kwak C, Lee SE, Jeong IG, Ku JH,. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology. 2006; 68: 53-57.
23. Lee SE, Byun SS, Park YH, Chang IH, Kim YJ, Hong SK,. Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Urol Int. 2006; 77: 22-26.
24. Soga N, Arima K, Sugimura Y,. Adjuvant methotrexate, vinblastine, Adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol. 2008; 15: 800-803.
25. Hellenthal NJ, Shariat SF, Margulis V, et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol. 2009; 182: 900-906.
26. Vassilakopoulou M, de la Motte Rouge T, Colin P, et al. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer. 2011; 117: 5500-5508.
27. Bamias A, Deliveliotis C, Fountzilas G, et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004; 22: 2150-2154.
28. Eylert MF, Hounsome L, Verne J, Bahl A, Jefferies ER, Persad RA,. Prognosis is deteriorating for upper tract urothelial cancer: data for England 1985-2010. BJU Int. 2012; 112: E107-E113.
29. Favaretto RL, Shariat SF, Savage C, et al. Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int. 2012; 109: 77-82.
30. Zigeuner R, Shariat SF, Margulis V, et al. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol. 2010; 57: 575-581.